Fails 3 of 8 criteria. S3, pharmacy identification: No filling pharmacy is named; the pages say prescriptions go to state-regulated compounding pharmacies and a licensed pharmacy partner in the United States. 2 more criteria also fail; see the table below.
At a glance
InstaRXTelehealth service
5/8criteria passed
Price
Semaglutide $179 a month and tirzepatide $259 a month at any dose
Sells
compounded semaglutide injections, compounded tirzepatide injections, and 2 more
Telehealth service. Passes 5 of 8 criteria. Recorded against Standard v1.1.
A telehealth platform selling compounded semaglutide and tirzepatide injections at one price for every dose, and NAD+ as injections or nasal spray. Its order path opens on a health quiz, and it names no filling pharmacy and prints two different business addresses.
The evidence behind each disposition in the table above, where it appears, and its date.
S1PASSEach assessment is reviewed by a licensed provider who determines the appropriate treatment, and the terms say care is provided by independent provider groups, naming Dr Telx and MDI Integrations.Source: InstaRX's website; InstaRX's terms and conditions.
S2PASSThe start button opens a health quiz whose first screen asks for height and weight to calculate a body mass index, with no price or payment field, and the site lists the health assessment as step one before the provider evaluation.Source: InstaRX's website; InstaRX's quiz storefront.
S3FAILNo filling pharmacy is named; the pages say prescriptions go to state-regulated compounding pharmacies and a licensed pharmacy partner in the United States.Source: InstaRX's GLP-1 weight loss page; InstaRX's terms and conditions; InstaRX's refund policy.
S4PASSThe home and GLP-1 pages state that compounded drugs are not FDA-approved and have not undergone FDA premarket review, and the safety pages say compounded semaglutide and compounded tirzepatide are not approved by the FDA. The pages also describe its partner pharmacies as FDA-regulated.Source: InstaRX's website; InstaRX's GLP-1 weight loss page; InstaRX's compounded semaglutide page; InstaRX's compounded tirzepatide page.
S5FAILThe product pages say the medication is independently verified in FDA and DEA registered labs and that potency and pH tests passed, but no certificate of analysis or lot document is published.Source: InstaRX's semaglutide injections product page; InstaRX's tirzepatide injections product page.
S6FAILThe seller prints two addresses: 521 5th Avenue, 17th Floor, New York, NY 10175 on its compounded GLP-1 and NAD+ pages, and 15061 Springdale St., Suite 206, Huntington Beach, CA 92649 on the contact page.Source: InstaRX's compounded semaglutide page; InstaRX's NAD+ plus page; InstaRX's contact page.
S7PASSCompounded semaglutide at $179 a month and compounded tirzepatide at $259 a month at any dose on the weight-loss page. The compounded semaglutide page prints $148 a month and the compounded tirzepatide page $265 a month, each for a 12-month prepayment, and the semaglutide product page prints $265 a month with the same prepayment note. NAD+ at $150 a month. The terms say a $45 doctor consultation fee is included in the monthly price.Source: InstaRX's weight loss page; InstaRX's compounded semaglutide page; InstaRX's compounded tirzepatide page; InstaRX's semaglutide injections product page; InstaRX's NAD+ plus page; InstaRX's terms and conditions.
S8PASSNo FDA warning letter names InstaRX or InstaRx, Inc., and no action has halted the business.Source: FDA warning-letter index.
Products shown on the seller's own pages at the recorded date: compounded semaglutide injections, compounded tirzepatide injections, NAD+ injections, NAD+ nasal spray.
Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.